These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 33535215)
1. T2-FLAIR Mismatch Sign and Response to Radiotherapy in Diffuse Intrinsic Pontine Glioma. Yamasaki F; Nishibuchi I; Karakawa S; Kaichi Y; Kolakshyapati M; Takano M; Yonezawa U; Imano N; Taguchi A; Shimomura M; Taniguchi M; Onishi S; Okada S; Awai K; Sugiyama K; Nagata Y Pediatr Neurosurg; 2021; 56(1):1-9. PubMed ID: 33535215 [TBL] [Abstract][Full Text] [Related]
2. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
3. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424 [TBL] [Abstract][Full Text] [Related]
4. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467 [TBL] [Abstract][Full Text] [Related]
6. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction. Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098 [TBL] [Abstract][Full Text] [Related]
7. Pediatric-type diffuse low-grade glioma with T2-FLAIR mismatch sign: a case report and literature review. Hwa JC; Wong AM; Jung SM; Wu CT Childs Nerv Syst; 2024 Aug; 40(8):2271-2278. PubMed ID: 38884778 [TBL] [Abstract][Full Text] [Related]
9. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma. Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811 [TBL] [Abstract][Full Text] [Related]
11. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis. Park SI; Suh CH; Guenette JP; Huang RY; Kim HS Eur Radiol; 2021 Jul; 31(7):5289-5299. PubMed ID: 33409784 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of synthetic MRI for differentiation of IDH-mutant diffuse gliomas and its comparison with the T2-FLAIR mismatch sign. Onishi S; Yamasaki F; Akiyama Y; Kawahara D; Amatya VJ; Yonezawa U; Taguchi A; Ozono I; Khairunnisa NI; Takeshima Y; Horie N J Neurooncol; 2024 Nov; 170(2):429-436. PubMed ID: 39133381 [TBL] [Abstract][Full Text] [Related]
13. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype. Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779 [TBL] [Abstract][Full Text] [Related]
14. T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity. Harward S; Harrison Farber S; Malinzak M; Becher O; Thompson EM Childs Nerv Syst; 2018 Mar; 34(3):449-455. PubMed ID: 29151166 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas. Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107 [TBL] [Abstract][Full Text] [Related]
17. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis. Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897 [TBL] [Abstract][Full Text] [Related]
18. T2-Fluid-Attenuated Inversion Recovery (FLAIR) Mismatch as a Novel Specific MRI Marker for Adult Low-Grade Glioma (LGG): A Case Report. Slaghour RM; Almarshedi RA; Alzahrani AM; Albadr F Cureus; 2022 Sep; 14(9):e29457. PubMed ID: 36299937 [TBL] [Abstract][Full Text] [Related]
19. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium. Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R; Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750 [TBL] [Abstract][Full Text] [Related]